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BASIC—LIVER, PANCREAS, AND BILIARY
TRACT
Ras Activity Levels Control the Development of Pancreatic Diseases
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YAN BI,¶ TOBIAS GROTE,* DANIEL S. LONGNECKER,# and CRAIG D. LOGSDON*,§
Departments of *Cancer Biology, ‡Pathology, §Gastrointestinal Medical Oncology, and Immunology, University of Texas M. D. Anderson Cancer Center, Houston,
Texas; ¶Department of Internal Medicine, University of Texas Medical Branch at Austin, Austin, Texas; and #Department of Pathology, Dartmouth Medical School,
Lebanon, New Hampshire
BACKGROUND & AIMS: Differentiated pancreatic
acinar cells expressing endogenous levels of mutant K-
Ras do not spontaneously develop pancreatic ductal ad-
enocarcinoma (PDAC). However, we hypothesized that
acinar cells would develop PDAC in the presence of Ras
activity levels mimicking those of human tumor cells.
METHODS: We measured Ras activity in PDAC cells
from mice and humans using a Raf pull-down assay. We
compared the effects of acinar cell expression of mutant
K-Ras at endogenous and elevated levels on Ras activity
and on the development of PDAC. RESULTS: Ras activ-
ity was greatly elevated in PDAC cells compared with
nontransformed cells expressing endogenous levels of
mutant K-Ras. Expression of endogenous levels of mu-
tant K-Ras in differentiated acinar cells resulted in mod-
erately elevated Ras activity and in sparse murine pancre-
atic intraepithelial neoplasias (mPanINs) that did not
spontaneously advance to PDAC unless the tumor sup-
pressor p53 was simultaneously deleted. In contrast, ex-
pression of mutant K-Ras at higher levels generated Ras
activity equal to that in PDAC. High Ras activity mim-
icking levels in PDAC led to acinar cell senescence and
generated inflammation and fibrosis resembling the his-
tologic features of chronic pancreatitis. With higher Ras
activity in acinar cells, abundant mPanINs formed and
spontaneously progressed to both cystic papillary carci-
noma and metastatic PDAC. CONCLUSIONS: There is
an important relationship between Ras activity levels
and the progression of PDAC. Sufficient Ras activ-
ity in pancreatic acinar induces several important
pancreatic disease manifestations not previously
reported and supports a potential direct linkage
between chronic pancreatitis, cystic papillary carci-
noma, and PDAC.
Pancreatic ductal adenocarcinoma (PDAC) is thefourth leading cause of cancer death in the United
States.1 Currently, there are no effective nonsurgical ther-
apies for this disease. Therefore, considerable efforts have
been made to develop animal models of PDAC useful for
developing and testing new treatments. Recently, mouse
models have been described that faithfully recapitulate
many important aspects of the human disease.2– 4 These
mouse models were developed by expression of activated
mutants of K-Ras at endogenous levels from its native
promoter in embryonic cells. These animals develop pre-
cursor lesions, mouse pancreatic intraepithelial neopla-
sias (mPanINs),2 which progress over the course of 1–2
years into PDAC resembling the human disease. These
models confirmed the potential role of K-Ras mutations
as an initiator of PDAC and validated a model of PDAC
progression starting from PanIN lesions and progressing
to metastatic disease.2,5
It is well known that activating Ras mutations can
induce either proliferation or senescence depending on
the activity levels. In the mammary gland, chronic low-
level Ras induction results in tumor formation only after
the spontaneous up-regulation of activated Ras and eva-
sion of senescence checkpoints.6 In the pancreas of mice
bearing targeted activating mutations at the endogenous
K-Ras locus, a minor subset of cells display hyperprolif-
eration and tumorigenesis.2,4 In these models, the levels
of Ras activity were significantly elevated in tumor lysates
compared with nontumor tissue expressing mutant K-
Ras.7 These findings suggested that increased Ras activity
may also play a crucial role in the process of pancreatic
tumorigenesis.
In this study, we examined the effects of elevating Ras
activity to different levels in pancreatic acinar cells in
genetically engineered mice. We found that pancreatic
Abbreviations used in this paper: CP, chronic pancreatitis; CPC,
cystic papillary carcinoma; GFP, green fluorescent protein; mPanIN,
murine pancreatic intraepithelial neoplasia; PDAC, pancreatic ductal
adenocarcinoma; TGF, transforming growth factor; TUNEL, terminal
deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-
end labeling.




























acinar cells were transformed by endogenous levels of
mutant K-Ras only in combination with genetic ablation
of the tumor suppressor p53. Interestingly, Ras activity
was greatly up-regulated in all PDAC cells examined,
whether mouse or human. Expression of high levels of
mutant K-Ras in acinar cells using a transgenic approach
led to levels of Ras activity similar to those found in
PDAC cells and caused mice to develop abundant
mPanINs, cystic papillary carcinoma (CPC), and PDAC.
High levels of Ras activity also led to widespread senes-
cence of acinar cells and the development of profound
inflammation and fibrosis resembling the histologic fea-
tures of human chronic pancreatitis (CP). Thus, a novel
model expressing elevated levels of mutant K-Ras in pan-
creatic acinar cells developed CP, CPC, and PDAC, pro-
viding the first evidence of a potential direct link between
these diseases.
Materials and Methods
Detailed materials and methods are described in
the Supplementary Materials and Methods.
Genetically Engineered Mice
cLGL-KRasG12V transgenic mice were produced by
pronuclear microinjection at the M. D. Anderson Can-
cer Center Genetically Engineered Mouse Facility. LSL-
KRasG12D and p53f/f conditional deletion mice were
obtained from the Mouse Models for Human Cancer
Consortium Repository (Rockville, MD).8,9 All animal
experiments were approved by the Institutional Animal
Care and Use Committees of the University of Texas
M. D. Anderson Cancer Center.
Ras Activity Assay
Total Ras activity was measured in cells lysed with
beads coated with Raf1-RBD (Upstate Biotechnology,
Lake Placid, NY).
Western Blot Analysis
To evaluate the levels of Ras, actin, RPS6, total
Erk, p-Erk, p-AKT, p53, and DEC1 expression, cell or
tissue lysates were separated by sodium dodecyl sulfate/
polyacrylamide gel electrophoresis and immunodetection
was performed as described in Supplementary Materials
and Methods.
Activation of K-Ras Expression in Primary
Pancreatic Acinar Cells With Cre-Bearing
Adenovirus In Vitro
Primary pancreatic acinar cells were prepared and
incubated with adenoviruses at a titer that was previously
shown to be nearly 100% efficient and incubated at 37°C
overnight.
Histology and Immunohistochemistry
Mice pancreata were fixed in 10% formalin and
embedded in paraffin. H&E staining was performed in
the M. D. Anderson Cancer Center Histology Core. Im-
munohistochemistry was performed using the RTU Vec-
tastain Elite ABC Universal Kit (Vector Laboratories, Bur-
lingame, CA).
-Galactosidase Activity Assays
Frozen sections were fixed in 2% formaldehyde/
0.2% glutaraldehyde in phosphate-buffered saline for 5
minutes and incubated with X-gal– containing reaction




Triphosphate Nick-End Labeling Assay
To evaluate apoptotic cells, we used the In Situ
Cell Death Detection Kit according to the manufacturer’s
suggestions (Roche, Indianapolis, IN).
Periodic Acid–Schiff and Sirius Red Staining
The mucin and collagen expression was stained
with periodic acid–Schiff reagents and Sirius Red stain-
ing (Sigma Chemical Co, St. Louis, MO).
Quantitative Reverse-Transcription
Polymerase Chain Reaction
Total RNA preparation and quantitative reverse-
transcription polymerase chain reaction (RT-PCR) were
performed as we previously described.10
Results
Targeted Expression of Endogenous Levels of
K-RasG12D in Pancreatic Acinar Cells Does
Not Lead to PDAC Unless Accompanied by
Loss of p53
To evaluate the effect of Ras activity specifically
in pancreatic acinar cells, we utilized mice in which a
tamoxifen-inducible Cre recombinase is expressed in
differentiated acinar cells by a full-length mouse pan-
creatic elastase I gene promoter (Ela-CreERT).11 These
mice exhibit tamoxifen-independent Cre activity after
birth specifically in acinar cells with high levels of
elastase expression, as has been fully described previ-
ously.11 Therefore, in the absence of tamoxifen, Cre
activity was restricted to well-differentiated acinar
cells. These mice were crossed with LSL-KRasG12D mice,
which express mutant K-RasG12D gene from the endoge-
nous K-Ras promoter after Cre recombination.8 Double-
transgenic mice (LSL-KRas/Ela-CreERT) in the absence
of tamoxifen developed typical mPanIN-1 lesions sur-
rounded by limited focal fibrosis beginning within 2–3
months (Figure 1A). The mPanINs occurred infrequently
in younger animals (1 or 2 per section), but their
number increased moderately over time (Figure 1B).
These lesions were similar to those described when de-
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of endogenous levels of mutant K-Ras.2 However, unlike
what was observed using developmental promoters, these
mPanIN-1 lesions did not progress to higher-grade
mPanINs or PDAC within 1.5 years of age (15/15). Yet,
when the LSL-KRas/Ela-CreERT mice were further
crossed with conditional p53 deletion mice (LSL-KRas/
p53f/f/Ela-CreERT), most of these mice developed PDAC
within 6 months (17/30) (Figure 1C). Therefore, acinar
cells are readily transformed by endogenous expression of
mutant K-Ras but only after a second genetic hit.
To determine the cellular origin of the mPanIN
lesions in this model, these mice were further crossed
with Rosa26R reporter mice (R26/LSL-KRas/Ela-CreERT).
In these triple-transgenic mice, mPanIN cells showed
-galactosidase activity, indicating the acinar lineage of
mPanIN lesions (Figure 1D). We also observed elevated
levels of p-Erk in mPanIN (Figure 1E) and PDAC cells
(Figure 1F) compared with acinar cells, which expressed
endogenous levels of mutant K-Ras (Figure 1E). These
data suggested that Ras activity was spontaneously up-
regulated during PDAC development.
Elevated Ras Activity in PDAC Cells Can Be
Mimicked by Transgenic Expression of
Mutant K-Ras
We next examined the level of Ras activity in
mouse models and human PDAC cell lines. Ras activity
was moderately elevated in most of the acinar cells in
pancreatic tissues expressing a single copy of mutant
K-Ras (Figure 2A), similar to what was previously re-
ported using a developmental promoter.2 In compari-
son, Ras activity was much more highly elevated in
PDAC cell lines derived from tumors formed in LSL-
KRas/p53f/f/Ela-CreERT mice (Figure 2A). Likewise,
signaling molecules downstream from Ras, including
p-Erk, were also more highly elevated in tumor cells
Figure 1. Targeted expression
of K-RasG12D to pancreatic acinar
cells at endogenous levels in-
duced nonprogressing mPanIN-1
lesions unless p53 was deleted.
(A) mPanIN lesions developed
in a 2-month-old LSL-KRas/Ela-
CreERT mouse. (B) The number of
mPanINs increased as the mice
aged but did not progress (15
months old). (C) Mice (LSL-KRas/
p53f/f/Ela-CreERT) that possessed
endogenous expression of mutant
K-Ras and p53 deletion readily de-
veloped PDAC (5 months old). (D)
For lineage tracing, LSL-KRas/Ela-
CreERT mice were further crossed
with Rosa26 reporter mice such
that cells of acinar lineage stained
for -galactosidase activity (blue).
All mPanINs cells stained blue. (E)
mPanIN cells (arrow) had elevated
levels of p-Erk compared with sur-
rounding acinar cells in a 4-month-
old LSL-KRas/Ela-CreERT mouse
detected using an anti–p-Erk anti-
body. (F) Cancer cells in PDAC de-
veloped from LSL-KRas/p53f/f/Ela-
CreERT mice (5 months old) also
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than in nontransformed cells with endogenous levels
of mutant K-Ras. Human PDAC cell lines with K-Ras
mutations also exhibited very high Ras activity (Figure
2B). These data further support the hypothesis that
Ras activity is spontaneously up-regulated during the
development of PDAC, as has previously been suggest-
ed.2
To directly study the effects of higher Ras activity,
we developed a new transgenic model in which
K-RasG12V was engineered following a human cytomeg-
alovirus and chicken ß-actin chimeric promoter
(CAG)12 and blocked by the proximal insertion of a
loxp-green fluorescent protein (GFP)-stop-loxp cas-
sette (cLGL-KRasG12V; Figure 2C). Transgenic mice car-
rying this construct expressed GFP in the whole body
(Figure 2D) before Cre recombination. The levels of
Ras activity were compared between freshly prepared
acinar cells isolated from LSL-KRasG12D and cLGL-
KRasG12V mice in vitro by infecting the cells with a
Cre-bearing adenovirus (AdCre). Under these condi-
tions, the Ras activity measured in the acinar
cells from the cLGL-KRasG12V mice after Cre-mediated
recombination was higher than that from LSL-
KRasG12D mice but was comparable to that observed in
Figure 2. Transgenic expres-
sion of mutant K-Ras mimicked
the elevated Ras activity levels
found in pancreatic cancer cells.
(A) Total Ras activity and p-Erk in-
creased in PDAC cell lines isolated
from LSL-KRas/p53f/f/Ela-CreERT
(LSL/p53f/f/Cre) mice compared
with untransformed pancreas tis-
sue lysate from LSL-KRas/Ela-
CreERT (LSL/Cre, 5 months old)
and wild-type control (Control)
mice. Deletion of p53 alone had
no effect on Ras activity (data not
shown). Ribosomal protein S6
(RPS6) was detected as a protein
loading control. (B) Ras activity in
human PDAC cells with K-Ras
mutations (MPanc96, Capan-1,
PANC-1, and L3.6) was signifi-
cantly higher than that in immor-
talized human pancreatic duct
cells (HPDE) and PDAC cells with-
out K-Ras mutation (BxPC3). (C)
Structure of the cLGL-KRasG12V
ectopic expression transgene.
K-RasG12V was engineered follow-
ing a human cytomegalovirus and
chicken ß-actin chimeric pro-
moter (CAG) and blocked by the
proximal insertion of a loxp-GFP-
stop-loxp cassette. (D) GFP was
expressed in the whole body of
cLGL-KRasG12V mouse (green)
but not in littermate controls
(gray). (E) Acini isolated from LSL-
KRasG12D and cLGL-KRasG12V
mice were infected either with a
control adenovirus (AdLacZ) or with
an adenovirus expressing Cre (Ad-
Cre). Ras activity was analyzed by
Raf pull-down and compared with
those in human PDAC cell lines or
mouse PDAC cell lines isolated
from LSL-KRas/p53f/f/Ela-CreERT
(LSL/p53f/f/Cre) mice. Total Ras, p-
Erk, p-AKT, and RPS6 were mea-
sured in Western blots from sam-
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human and mouse PDAC cell lines (Figure 2E). Like-
wise, levels of p-Erk and p-AKT, indicators of Ras
pathway activity, were also comparable between the
cLGL-KRasG12V cell and human PDAC cells but higher
than those observed in the LSL-KRasG12D cells (Figure
2E). Thus, transgenic expression of mutant K-Ras
achieved levels of Ras activity and downstream signal-
ing that were similar to those observed in mouse and
human PDAC cells.
Higher Levels of Acinar Cell Ras Activity
Induce Inflammation and Fibrosis That
Mimic the Histologic Features of Human CP
To study the effects of a higher level of Ras activ-
ity in the pancreas, cLGL-KRasG12V mice were crossed
with the Ela-CreERT mice, and pups were allowed to
develop in the absence of tamoxifen treatments. Five days
after birth, the pancreata from double-transgenic mice
showed few obvious differences in size, shape, or color
from littermate controls. Histologically these pancreata
showed some signs of acinar-to-ductal metaplasia but
were otherwise normal (Figure 3A). From 6 days, the
pancreata from double-transgenic mice became firmer
and bigger than those of the littermate controls. In adult
mice, the pancreata became smaller than those of con-
trols (Supplementary Figure 1). Histologically, changes in
the pancreas in these mice as they aged involved a pro-
gression from normal pancreas to extensive fibrosis re-
sembling CP (Figure 3A–C). CP was characterized by loss
of acinar cells, acinar-to-ductal metaplasia, leukocyte in-
filtration, and replacement by stroma with collagen dep-
osition (Supplementary Figure 1C). Cells observed within
the stroma displayed pronounced smooth muscle actin
staining (Figure 3D), which suggested that they were
activated stellate cells.13
The loss of acinar cells that occurred in this model was
associated with the expression of senescence-associated
-galactosidase (Figure 4A), with little evidence of ap-
optosis (Figure 4B). DEC1, another marker of senes-
cence,14 was dramatically increased early in this model
(Figure 4C). Tumor suppressor genes p53, p15, and p16,
which are known to be involved in oncogene-induced
senescence, were also elevated (Figure 4C and D). Senes-
cent cells induced by oncogenic Ras in vitro have been
reported to develop a senescence-associated secretory
phenotype, which results in the secretion of inflamma-
tory cytokines.15 We found in this in vivo model that
high levels of Ras activity induced increased expression of
interleukin-1, interleukin-6, Gro-, and granulocyte-
macrophage colony–stimulating factor (Figure 4F).
Elevated Levels of Ras Activity in Acinar
Cells Result in Rapid Development of
mPanIN, CPC, and PDAC
In the background of CP, we observed the forma-
tion of multifocal acinar-to-ductal metaplasia in the pan-
Figure 3. High levels of Ras ac-
tivity in pancreatic acinar cells
led to the development of CP.
(A) At 5 days after birth, pancre-
ata from cLGL-KRas/Ela-CreERT
mice showed normal histology
except for occasional sites of
acinar-to-ductal metaplasia. (B)
At 9 days after birth, acinar cells
were depleted from many areas
with the development of fibrotic
stroma. (C) In adult mice (2
months), the fibrosis expanded
with abundant intercellular colla-
gen deposition. (D) The stromal
compartment of the pancreas (2
weeks old) showed abundant
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creas from all (100%) cLGL-KRasG12V/Ela-CreERT mice
(Figure 5A). In younger mice, we observed primarily
mPanIN-1 (Figure 5B) and occasionally mPanIN-2 lesions
(Figure 5C). As the animals aged, there was an increase in
the level of dysplasia and in the frequency of mPanIN-3
lesions (Figure 5D). Three out of 20 mice developed
noninvasive CPC, which were composed of large cystic
lesions (1.0 mm) lined with highly dysplastic ductal
epithelial cells forming finger-like papillae (Figure 5E).
The frequencies of mPanIN lesions of different histologic
grades developed by different age groups are shown in
Figure 5F. Acinar-to-ductal metaplasia and mPanINs in
these mice exhibited typical characteristics similar to
what were observed in other models (Supplementary Fig-
ure 2A–F).2
At 4 months of age, one mouse developed PDAC (Fig-
ure 6A) with metastasis to the liver (Supplementary Fig-
ure 2G) and lungs (data not shown). By 6 months of age,
29% of mice (7/24) developed PDAC. At 9 months, the
incidence for PDAC increased to 50% (10/20). Metastatic
PDAC cells were also identified in peripancreatic lymph
nodes (Figure 6B). Some mice showed extensive tumor
invasion into the diaphragm (Figure 6C). All tumors were
adenocarcinomas composed of neoplastic glands, similar to
those seen in human PDAC. No staining of the acinar cell
marker, amylase, was detected by immunohistochemistry
(Supplementary Figure 2H). The tumors were moderately to
poorly differentiated, with 10%–40% desmoplastic tumor
stroma. Negative staining for GFP supported that the
PDAC cells originated from pancreatic acinar cells (Figure
6D).
To further evaluate the levels of Ras activity in PDAC
cells developed from different models, we measured Ras
activity in cancer cell lines developed from LSL-KRas/
p53f/f/Ela-CreERT and cLGL-KRas/Ela-CreERT mice as
well as human PDAC cell lines (Figure 6E). We observed
comparable levels of Ras activity in each of these cancer
cell lines, suggesting that Ras activity progressed to peak
levels in PDAC cells even when the cancers were initiated
with endogenous levels of mutant K-Ras expression. All 4
independent cancer cells from cLGL-KRas/Ela-CreERT
mice lost expression of p15 and p16 but retained p53
(Figure 6F). These p53 were verified as wild-type by DNA
sequencing. Conversely, cancer cells from LSL-KRas/p53f/f/
Ela-CreERT mice lacked p53 expression as expected but
retained intact p15 and p16 (Figure 6F).
Discussion
In this study, we investigated the importance of
Ras activity levels in the development of PDAC. We
showed that the level of Ras activity in PDAC cells,
whether mouse or human, is highly elevated. We con-
firmed that adult pancreatic acinar cells are largely re-
Figure 4. Elevated Ras activity in
pancreatic acinar cells caused aci-
nar cell senescence and stellate cell
activation. (A) In adult cLGL-KRas/
Ela-CreERT mice (2 months old),
many acinar cells stained positive
for senescence-associated -ga-
lactosidase. (B) Few pancreatic aci-
nar cells showed apoptosis (arrow)
as indicated by terminal deoxynu-
cleotidyl transferase–mediated de-
oxyuridine triphosphatenick-end la-
beling (TUNEL) assay (2 months
old).Deoxyribonuclease-treated tis-
sue served as a positive control
(inset). (C) DEC1 and p53 were
up-regulated in cLGL-KRas/Ela-
CreERT (cLGL/Cre)mice (2months
old) as measured by Western blot.
(D) Quantitative reverse-transcrip-
tion polymerase chain reaction
showed that p15, p16, interleukin-
1, interleukin-6, Gro-, and gran-
ulocyte-macrophage colony–stim-
ulating factor were up-regulated
(shown in log2 scale) incLGL-KRas/
Ela-CreERT mice (1 month old) as
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fractory to endogenous levels of mutant K-Ras4,16,17 and
showed for the first time that this resistance can be
readily overcome by deletion of p53. Furthermore, we
observed that levels of Ras activity that mimicked the
levels found in PDAC cells had profound effects on
acinar cells that have not been reported previously, in-
cluding the spontaneous development of CP, CPC, and
PDAC. Therefore, our data indicate that the levels of Ras
activity are of great importance in the development of
pancreatic diseases.
It was previously reported that levels of Ras activity
were significantly elevated in bulk tumor tissues from
mice expressing endogenous levels of K-Ras, although it
was unclear if the elevated activity reflected increased
signaling in cancer cells or an alteration in the balance of
cell types in the tumors.7 In the current study, we iden-
tified the cancer cells themselves as the source of this
high Ras activity. We also observed that both mouse and
human PDAC cells possessed greatly elevated Ras activity
compared with untransformed cells expressing endoge-
nous levels of mutant K-Ras. When these high levels of
Ras activity were directly mimicked by transgenic expres-
sion of mutant K-Ras in pancreatic acinar cells, we ob-
served the development of senescence, diffuse CP, acinar-
to-ductal metaplasia, multifocal mPanINs, and a high
incidence of PDAC at a relatively early age. These data
support the concept that a threshold of Ras activity is
important for the induction of cellular transformation
Figure 5. High levels of Ras ac-
tivity caused acinar-to-ductal
metaplasia and led to the forma-
tion of mPanINs and CPC. (A) In
cLGL-KRas/Ela-CreERT mice (2
months old), acinar-to-ductal
metaplasia (arrows) was ob-
served. (B–E) Transgenic ex-
pression of mutant K-Ras in-
duced typical mPanINs that
progressed over time, including
mPanIN-1 (B, 2 months),
mPanIN-2 (C, 4 months), and
mPanIN-3 (D, 6 months) lesions
and CPC (E, 7 months). (F) The
grade of the mPanIN lesions
present in the pancreas of trans-
genic animals progressed with
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and that this level can be achieved spontaneously in
models with endogenous levels of mutant K-Ras expres-
sion6 or directly by expression of higher levels of mutant
K-Ras.
The mechanisms responsible for the stochastic events
resulting in the elevation of Ras activity in cells express-
ing mutant K-Ras from the endogenous promoter are
currently unknown. It may be partly explained by the
common phenomenon of amplification of the mutant
K-Ras allele.7 However, other alterations in signaling
pathways may also contribute to the increased Ras activ-
ity independently or in addition to K-Ras mutation. For
example, it has also been observed that combining low
levels of expression of mutant K-Ras with other stimuli
known to increase Ras activity such as transforming
growth factor (TGF)-18 or cholecystokinin4 leads to
much more profound phenotypes. This supports the
concept that up-regulated Ras pathway activity by extrin-
sic stimuli may also play an important role in transfor-
mation.
The current study confirmed previous observations
that low endogenous levels of Ras activity are insuffi-
cient to transform fully differentiated pancreatic aci-
nar cells.4,16,19 However, it also shows for the first time
that combination of p53 deletion with endogenous
levels of mutant K-Ras in acinar cells readily leads to
PDAC. Furthermore, we observed that adult acinar
cells were spontaneously transformed by elevated levels
of mutant K-Ras expression that resulted in levels of
Ras activity similar to those observed in PDAC cells.
Taken together, these data support that pancreatic
acinar cells can be a cell origin of PDAC, providing
elevated Ras activity and loss of tumor suppressor
genes occurs.
Figure 6. Invasive and meta-
static PDAC developed sponta-
neously from pancreatic acinar
cells with levels of Ras activity
that mimicked those of human
PDAC. (A) PDAC developed in
cLGL-KRas/Ela-CreERT mice (4
months). (B) Metastatic cancer
cells (arrow) were observed in
the lymph nodes. (C) Some
PDAC invaded the diaphragm.
(D) GFP expression was lost in
cancer cells (arrows), suggesting
they were of pancreatic acinar
origin. (E) Ras activity was mea-
sured in 3 independent cancer
cell l ines developed from
LSL-KRas/p53f/f/Ela-CreERT
(LSL/p53/Cre Cells) mice and
cLGL-KRas/Ela-CreERT (cLGL/
Cre Cells) and compared with
those found in human PDAC
cells. (F) Reverse-transcription
polymerase chain reaction mea-
surement showed that cancer
cells from cLGL-KRas/Ela-CreERT
(cLGL/Cre Cells) mice lost ex-
pression of p15 and p16 but re-
tained p53. In contrast, cancer
cells from LSL-KRas/p53f/f/Ela-
CreERT (LSL/p53/Cre Cells)
mice lost p53 expression but re-
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In 2 previous studies in which endogenous mutant
K-Ras expression was initiated by elastase4 or pdx1 pro-
moters,20 CP induced by secretagogue administration
was found to accelerate PDAC formation. This study
differs from previous ones in that higher levels of Ras
activity drove both CP and spontaneous PDAC in the
absence of additional treatments. Thus, Ras activity
above a threshold is sufficient for both inflammatory and
transforming responses. Of note, the treatments com-
monly utilized to induce pancreatitis also activate Ras.21
Therefore, one possible explanation for the previous ob-
servations is that the treatments used to generate inflam-
mation themselves elevated the level of Ras activity above
a threshold leading to the observed effects.
These data support a model in which there are 2
significant barriers to PDAC development, as have been
previously proposed in mammary cancer.6,22 One barrier
is the elevation of levels of Ras activity beyond a critical
threshold. This barrier can be overcome either by in-
creased extrinsic Ras activators, such as coexpression of
TGF-23 or administration of cholecystokinin,4,20 or, as
in the current study, by elevated expression of mutant
K-Ras. Yet, even with high levels of Ras activity, there
remains a latency of several months before tumors form.
Furthermore, elevated Ras activity primarily drives cellu-
lar senescence rather that tumorigenesis. Thus, another
barrier, the loss of tumor suppressors, is required for
evasion of oncogene-induced senescence and full trans-
formation. As shown here and in other studies, deletion
or mutation of p53,24 p16,7 or p1925 can dramatically
accelerate tumor formation. These 2 barriers are not
independent. Loss of tumor suppressors is permissive for
cells with spontaneously up-regulated Ras activity to
evade oncogene-induced senescence. It also appears that
the spontaneous loss of tumor suppressors is accelerated
by high levels of Ras activity, likely due to the associated
increase in genetic instability.26
Another major finding in this study was that Ras
activity at levels similar to those observed in PDAC cells
drove the development of an inflammatory phenotype
similar to the histologic features of human CP. This
observation raises an issue concerning the commonly
observed presence of K-Ras mutations in CP. It has been
well recognized that K-Ras mutations are present in
nearly all PDAC.27,28 However, it is less well appreciated
that K-Ras mutations are also found in nearly 30%– 40%
of patients with CP.29 The biological significance of K-
Ras mutations in CP has not been understood. One
popular hypothesis is that prolonged inflammatory con-
ditions of CP increase the probability of gene mutations,
as has been reported.30 However, K-Ras mutations have
also been observed in hyperplastic ducts within normal
pancreas.31 Therefore, it is likely that K-Ras mutations
can occur before the development of CP. In the current
study, we observed that elevation of Ras activity in pan-
creatic acinar cells led directly to CP. Thus, our study
provides evidence of a potential functional relationship
between K-Ras mutations and CP in which mutant K-Ras
is a cause rather than a secondary effect of CP. The
present study also suggests that the activity level, rather
than the presence of mutations, is the critical parameter.
It is intriguing to speculate that the inflammatory re-
sponse observed in this study may have been associated
with the induction of senescent cells by high levels of Ras
activity. Senescent cells are known to secrete myriad fac-
tors associated with inflammation.15 This animal model
should be useful for future studies to elucidate the se-
nescence-associated secretory phenotype and the devel-
opment of fibrosis in vivo. It is noted that not all pan-
creases of patients with CP possess K-Ras mutations.
However, it is known that the Ras signaling pathway is
activated by several stimuli known to cause CP in mouse
models, including cholecystokinin treatments,21 expres-
sion of cyclooxygenase-2,32 and expression of TGF-.33
Thus, we speculate that increases of Ras activity in pan-
creatic acinar cells brought about by various treatments
may mediate the development of fibrosis and inflamma-
tion even in the absence of K-Ras mutations. Whether
these concepts apply to the human disease will require
further investigation.
We also observed that acinar cells gave rise to CPC in
the mouse model with higher levels of Ras activity. This
Figure 7. Ras activity levels control the development of pancreatic
diseases. For the initiation of pancreatic diseases, Ras activity levels
must be elevated beyond a threshold. This can be accomplished either
by high levels of extrinsic Ras activators (extrinsic pathway) or intrinsic
alterations of Ras activity including activating mutations of K-Ras (intrin-
sic pathway) or by a combination of these 2 pathways. Once reached,
levels of Ras activity above a threshold cause acinar cells to undergo
acinar-to-ductal metaplasia and to form PanINs. High levels of Ras
activity also lead to the generation of inflammation resembling CP.
Inflammation-induced genetic instability likely increases the probability
of genetic alterations including mutations in K-Ras and loss of tumor
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is the first evidence that acinar cells can give rise to this
pathological condition. In mouse models, cystic papillary
neoplasms are defined as large (1 mm) cystic structures
composed of usually papillary, noninvasive epithelial
proliferations with varying degrees of cellular atypia.
These lesions resemble human intraductal papillary mu-
cinous neoplasms,4,34 which are considered an important
precursor lesion to PDAC.35 In a recent study in trans-
genic mice, it was observed that a combination of expres-
sion of mutant K-Ras with overexpression of TGF- was
able to lead to the development of structures resem-
bling intraductal papillary mucinous neoplasm.21 In that
study, it was suggested that the CPCs did not originate
from pancreatic acinar cells based on the observation
that the cells in the CPCs did not express acinar-specific
genes. However, in the current study, we observed that
acinar cells rapidly lost differentiated gene expression
upon metaplasia such that it is difficult to know the cell
of origin without lineage tracing.
In summary, elevated Ras activity plays a crucial role in
the development of pancreatic cancer and provides a
possible direct linkage between CP, CPC, and PDAC.
Based on our observations and taking into account ob-
servations from other models, we propose a scheme to
explain the role of Ras activity in progression of pancre-
atic disease (Figure 7). According to this mechanistic
view, 2 key obstacles to the formation of PDAC are
achievement of a high level of Ras activity and the loss of
tumor suppressors. High levels of Ras activity also gen-
erate an inflammatory response resembling CP that likely
accelerates genetic changes. The animal model described
in this study will provide a powerful tool for further
investigations of the mechanisms underlying CP, pancre-
atic cancer, and the transition between these diseases.
Supplementary Data
Note: To access the supplementary material
accompanying this article, visit the online version of
Gastroenterology at www.gastrojournal.org, and at doi:
10.1053/j.gastro.2009.05.052.
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Supplementary Materials and Methods
Genetically Engineered Mice
To generate cLGL-KRasG12V, a fragment contain-
ing loxP-GFP-stop-loxP followed by K-RasG12V was cloned
into pCAGGS vector (gift from Dr Miyazaki, Kumamoto
University Medical School, Kumamoto, Japan), which
contains a cytomegalovirus (CMV) and chicken -actin
chimeric promoter.1 For pronuclear injection, cLGL-
KRasG12V was digested with SpeI and HindIII to remove
vector sequences and the cLGL-KRasG12V DNA fragments
were purified. LSL-KRasG12D mice (Donated by Dr Tyler
Jacks, Massachusetts Institute of Technology, Cam-
bridge, MA) and p53f/f conditional deletion mice (do-
nated by Dr Anton Berns, Netherlands Cancer Institute,
Amsterdam, The Netherlands) were obtained from the
Mouse Models for Human Cancer Consortium Reposi-
tory (Rockville, MD).2,3
Ras Activity Assay
Cells were lysed on ice in 25 mmol/L HEPES (pH
7.5) containing 1% Igepal CA-630 (Sigma, St. Louis, MO),
150 mmol/L NaCl, 10 mmol/L MgCl2, 1 mmol/L EDTA,
10% glycerol, 10 g/mL aprotinin, 10 g/mL leupeptin,
25 mmol/L sodium fluoride, and 1 mmol/L sodium or-
thovanadate and cleared by centrifugation at 15,340g for
5 minutes at 4°C. Aliquots of lysates were set aside to
allow quantification of total Ras or protein loading con-
trols by immunoblotting. Equal amounts of lysate pro-
tein were incubated for 45 minutes at 4°C, with beads
coated with Raf1-RBD (Upstate Biotechnology, Inc, Lake
Placid, NY). Beads were then washed 3 times with ice-cold
lysis buffer, and bound protein was eluted for 15 minutes
with 2 Laemmli sample buffer that had been preheated
to 95°C and analyzed by immunoblotting for Ras fol-
lowing Western blot analysis protocol.
Western Blot Analysis
To evaluate the levels of Ras, actin, RPS6, total
Erk, p-Erk, p-AKT, p53, and DEC1 expression, cell or
tissue lysates were separated by sodium dodecyl sulfate/
polyacrylamide gel electrophoresis and immunodetection
was performed with the Odyssey fluorescent imager (Li-
Cor Biosciences, Lincoln, NE).
Cell or tissue lysates were prepared, separated by so-
dium dodecyl sulfate/polyacrylamide gel electrophore-
sis, and transferred to nitrocellulose. Membranes were
blocked for 1 hour at room temperature with 3% nonfat
milk in Tris-buffered saline containing 0.1% Tween 20
(TBST), washed, and incubated overnight at 4°C with
one of the following primary antibodies: anti–K-Ras (1:
10,000; Upstate Biotechnology, Inc, Lake Placid, NY),
anti-actin (1:1000; Sigma Chemical Co, St Louis, MO),
anti-RPS6 (1:1000; Santa Cruz Biotechnology, Santa
Cruz, CA), p-Erk and p-AKT antibodies (1:1000; Cell
Signaling Technology, Danvers, MA), and anti-Dec1 (0.25
g/mL; Aviva Antibody Corp, San Diego, CA). Immuno-
detection was performed with the corresponding Alexa
Fluor 680 – conjugated secondary antibodies. Fluores-
cence was detected with the Odyssey fluorescent imager
(Li-Cor Biosciences), and images were converted to gray
scale.
Activation of K-Ras Expression in Primary
Pancreatic Acinar Cells With Cre-Bearing
Adenovirus In Vitro
A recombinant adenovirus encoding the Cre re-
combinase (AdCre) was produced according to the
method of He et al.4 Briefly, a DNA fragment encoding
the full-length Cre recombinase was ligated behind the
CMV promoter of pAd-Track-CMV shuttle vector, pro-
ducing pAd-Track-CMV-Cre plasmid. Under the control
of a distinct CMV promoter, this plasmid also expresses
GFP. The construct was linearized with PmeI and cotrans-
fected together with the adenoviral backbone vector,
pAd-Easy-1, into Escherichia coli strain BJ5183. Recombi-
nant cosmids were selected with kanamycin and screened
by BamHI and PacI digestion. The adenoviral construct
was then cleaved with PacI and transfected in a packaging
cell line (human embryonic kidney 293 cells) to produce
AdCre. An adenovirus (AdLacZ) expressing bacterial -ga-
lactosidase and GFP, each under the control of a separate
CMV promoter, was a gift from Dr He (John Hopkins
Oncology Center, Baltimore, MD) and utilized as a con-
trol. The recombinant virus was concentrated using a
CsCl gradient. The titer of the viral stocks was estimated
based on the density of GFP-expressing cells.
Primary pancreatic acinar cells were prepared by meth-
ods previously described.5 In brief, the pancreata from
cLGL-KRasG12V mice were excised, and pancreatic acini
were prepared by enzymatic digestion with purified col-
lagenase, followed by mechanical shearing. Acini were
then filtered through 150-m Nitex mesh and purified by
sedimentation through 4% bovine serum albumin in Dul-
becco’s modified Eagle medium (DMEM). The acini were
suspended in DMEM containing 1% bovine serum albu-
min in the presence of 0.1 mg/mL soybean trypsin inhib-
itor. AdCre or AdLacZ at a titer of 107 plaque-forming
units/mg protein were added to acini in 3 mL of DMEM
for 10 minutes. The acini were then diluted with DMEM
to 13 mL, transferred to 100-mm dishes, and incubated
at 37°C in a humidified 5% CO2 atmosphere overnight.
Histology and Immunohistochemistry
Mice pancreata were fixed in 10% formalin and
embedded in paraffin. H&E staining was performed in
the M. D. Anderson Cancer Center Histology Core. For
immunohistochemistry, unstained sections were deparaf-
finized with xylene and rehydrated in water. Immunohis-
tochemistry was performed using RTU Vectastain Elite
ABC Universal Kit (Vector Laboratories, Burlingame, CA)
according to the manufacturer’s instructions. Sections
were treated with primary antibodies diluted in 2% bo-
vine serum albumin/0.2% Triton X-100 in phosphate-
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buffered saline (PBS) overnight followed by incubation
with corresponding horseradish peroxidase–labeled sec-
ondary antibody. Finally, slides were developed with 3,3-
diaminobenzidine substrate and counterstained with he-
matoxylin, dehydrated with ethanol, fixed with xylene,
and mounted. Primary antibodies anti-GFP (1:1000) and
anti–smooth muscle actin (1:100) were purchased from
Abcam (Cambridge, MA). Anti–proliferating cell nuclear
antigen (1:100), anti– cyclooxygenase-2 (1:50), anti-amy-
lase (1:200), and anti–Hes-1 (1:50) antibodies were pur-
chased from Santa Cruz Biotechnology. p-Erk antibody
(1:100) was from Cell Signaling Technology.
-Galactosidase Activity Assays
For detection of -galactosidase activity in mice
bearing the Rosa26 floxed gene,6 frozen sections were
fixed in 0.2% glutaraldehyde, 50 mmol/L ethylene glycol-
bis(-aminoethyl ether)-N,N,N=,N=-tetraacetic acid, and
100 mmol/L MgCl2 in PBS for 15 minutes and then
washed 3 times with PBS followed by staining in X-gal
solution (pH 7.4) containing 1 mg/mL X-gal, 5 mmol/L
potassium ferricyanide, 2 mmol/L potassium ferrocya-
nide, 2 mmol/L MgCl2, 0.01% sodium deoxycholate, and
0.02% Nonidet P-40 at 37°C overnight. To measure se-
nescence-associated -galactosidase activity,7 frozen sec-
tions were fixed in 2% formaldehyde/0.2% glutaraldehyde
in PBS for 5 minutes and incubated with X-gal– contain-
ing reaction mixture (pH 6.0) provided by the manufac-
turer (Millipore, Billerica, MA).
TUNEL Assay
To evaluate apoptotic cells, we used the In Situ
Cell Death Detection Kit according to the manufacturer’s
suggestions (Roche, Indianapolis, IN). Basically, histo-
logic sections were treated with proteinase K in Tris-HCl
(pH 7.5) at room temperature, rinsed with PBS, and
incubated in 0.3% H2O2 in methanol for 30 minutes.
After permeabilization in 0.1% Triton X-100 in sodium
citrate buffer, sections were incubated with the TUNEL
reaction mixture containing terminal transferase and bi-
otin-16-deoxyuridine triphosphate. After washing, the
slides were treated with horseradish peroxidase– conju-
gated streptavidin followed by chromagen 3,3=-diamino-
benzidine tetrahydrochloride. Positive controls were pre-
pared by adding 1 U/L deoxyribonuclease for 10
minutes.
Periodic Acid–Schiff and Sirius Red Staining
The mucin expression was stained with periodic
acid–Schiff reagents according to the manufacturer’s in-
structions (Sigma Chemical Co). Briefly, pancreas sec-
tions were deparaffinized, hydrated to deionized water,
and then immersed in periodic acid solution for 5 min-
utes at room temperature. After washing with distilled
water, the slides were incubated in Schiff’s reagent for 15
minutes followed by counterstaining with hematoxylin
solution. The glycol-containing mucin stains pink to red.
The presence of collagen was revealed with Sirius Red
staining (Sigma Chemical Co). In brief, slides were depar-
affinized and hydrated to water and nuclei were stained
with Weigert’s hematoxylin for 8 minutes. Following 10
minutes of washing in running tap water, the slides were
stained in picro-Sirius Red solution containing 0.1%
Sirius Red in saturated aqueous solution of picric acid
for 1 hour. Collagen-rich tissue is stained red on a pale
yellow background.
Reverse-Transcription Polymerase Chain
Reaction and Quantitative Reverse-
Transcription Polymerase Chain Reaction
Standard reverse-transcription polymerase chain
reaction (RT-PCR) was conducted using total RNA pre-
pared from mouse tissues or cell lines isolated using
TRIzol reagent (Invitrogen, Carlsbad, CA). RNA was fur-
ther purified by digestion for 15 minutes with deoxyri-
bonuclease and recovery of RNA using an RNeasy kit
(Qiagen, Valencia, CA). Reverse transcription was con-
ducted for 45 minutes at 48°C from 1 g of purified
total RNA in a 25 L volume of Access RT-PCR reaction
mixture (Promega, Madison, WI) followed by 40 cycles of
standard PCR (30 seconds of denaturation at 94°C, 1
minute of annealing at 60°C, and 1.5 minutes of exten-
sion at 68°C). Quantitative RT-PCR was conducted using
SYBR green I to monitor the PCR products on the
I-Cycler thermal cycler and IQ real-time PCR detection
system (Bio-Rad, Hercules, CA). Primers were designed to
span at least one intron to further eliminate the influence
of genomic DNA contamination in the RNA preparation.
RPS6 gene was used as an internal RNA loading control.
Primers sequences were as follows: p15 (GenBank accession
NM_007670; forward, CGGCGAAGGACCATTTCTG; re-
verse, GTTCAGGGCGTTGGGATC), p16 (GenBank acces-
sionNM_009877; forward, GTGCGATATTTGCGTTCC;
reverse, CTCTGCTCTTGGGATTGG), p53 (GenBank ac-
cession NM_011640; forward, TGAACCGCCGACCTA-
TCCTTACC; reverse, CCCAGGGCAGGCACAAACAC), p53
full length (GenBank accession NM_011640; forward, CT-
TCCCAGCAGGGTGTCACGCT; reverse, GGACGGGATG-
CAGAGGCAGTCA), interleukin-1 (GenBank accession
NM_008361; forward, GCACTACAGGCTCCGAGATG; re-
verse, GTCGTTGCTTGGTTCTCCTTG), interleukin-6 (Gen-
Bank accession NM_031168; forward, AGACAAAGCCA-
GAGTCCTTCAG; reverse, AGCCACTCCTTCTGTGACTCC),
Gro- (GenBank accession NM_008176; forward,
CGAAGTCATAGCCACACTCAAG; reverse, CCAGACGGT-
GCCATCAGAG), granulocyte-macrophage colony–stimu-
lating factor (GenBank accession NM_009969; forward,
AGACCCGCCTGAAGATATTCG; reverse, CCGCATAGGT-
GGTAACTTGTG), and RPS6 (GenBank accession NM_
009096; forward, GATGTCCGCCAGTATGTTGTC; reverse,
TCTTAGTGCGTTGCTTCTTCAG).
To detect possible mutations of p53 gene in cLGL-
KRasG12V/Ela-CreERT mice, we directly sequenced the
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open reading frames for p53 after RT-PCR amplification





From 6 days, the pancreata from cLGL-KRas/Ela-
CreERT double-transgenic mice became firmer and big-
ger than those of the littermate controls (Supplementary
Figure 1A). In adult mice, the pancreata became smaller
than those of controls (Supplementary Figure 1B). His-
tologically, normal pancreas was replaced by stroma with
collagen deposition (Supplementary Figure 1C).
Characteristics of mPanINs in cLGL-KRas/
Ela-CreERT Mice
High mucin content was observed in mPanINs
(Supplementary Figure 2A). Focal mucin staining was
also observed in cells with acinar morphology in regions
of acinar-to-ductal metaplasia, indicating that mucin ex-
pression is an early event in the transitional state of
acinar cells undergoing metaplasia (Supplementary Fig-
ure 2A, arrows). As in previous models, mPanIN cells
showed activated Notch signaling, which was indicated
by nuclear staining of transcription factor Hes1 (Supple-
mentary Figure 2B). Senescence-associated -galactosi-
dase was expressed in mPanINs (Supplementary Figure
2C), suggesting that oncogene-induced senescence may
be crucial to limit mPanIN progression and cancer devel-
opment. In mPanINs, most cells lost expression of the
pancreatic acinar cell marker amylase (Supplementary
Figure 2D). p-Erk was increased in mPanIN cells (Sup-
plementary Figure 2E) and cancer cells (Supplementary
Figure 2F) developed from cLGL-KRas/Ela-CreERT mice.
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Supplementary Figure 1. High level of Ras activity in pancreatic acinar cells induced CP. (A) Pancreata (formalin-fixed) from cLGL-KRas/Ela-
CreERT (cLGL/Cre) double-transgenic mice were bigger and firmer (right) than those from wild-type mice (left) at 2 weeks after birth. (B) Pancreata
(without fixation) from cLGL-KRas/Ela-CreERT (cLGL/Cre) double-transgenic mice were smaller and firmer (right) than those from wild-type mice (left)
in adult mice. (C) The abundant stroma in the pancreatic tissue of double-transgenic mice (2 months old) showed pronounced staining for collagen
with Sirius Red.
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Supplementary Figure 2. Acinar-to-ductal metaplasia and mPanINs in the transgenic model with high levels of mutant K-Ras exhibited typical
characteristics. (A) In adult cLGL-KRas/Ela-CreERT double-transgenic mice (2 months old), periodic acid–Schiff (PAS) staining indicated abundant
mucin (red) in ductal structures and acinar cells undergoing acinar-to-ductal metaplasia (arrows). (B) Hes1, a Notch-signaling target gene normally
present during pancreatic development, was up-regulated and localized to the nucleus (brown) in mPanINs (arrows). (C) Senescence, indicated by
senescence-associated -galactosidase expression, was present in mPanINs (blue). (D) Amylase expression, a marker of differentiated acinar cells,
was analyzed using an anti-amylase antibody in sections taken from a cLGL-KRas/Ela-CreERT mouse pancreas. This acinar cell marker was lost in
cells within mPanINs (arrowheads) but not in adjacent acinar cells (arrows). (E) p-Erk was stained by immunohistochemistry in mPanIn cells from a
cLGL-KRas/Ela-CreERT mouse. (F) PDAC developed from a cLGL-KRas/Ela-CreERT mouse showed strong p-Erk staining. (G) PDAC developed in
cLGL-KRas/Ela-CreERT mice (4 months) metastasized to liver. (H) Amylase expression was absent in pancreatic cancer cells in cLGL-KRas/
Ela-CreERT mice (arrows).
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